CATALOGO DEI PRODOTTI DELLA RICERCA

SCAFFIDI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.418
EU - Europa 2.000
AS - Asia 1.854
SA - Sud America 291
AF - Africa 51
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 6.652
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.346
RU - Federazione Russa 905
SG - Singapore 695
CN - Cina 546
GB - Regno Unito 289
BR - Brasile 240
IT - Italia 217
HK - Hong Kong 182
VN - Vietnam 163
DE - Germania 125
SE - Svezia 111
FR - Francia 110
IE - Irlanda 93
KR - Corea 57
BD - Bangladesh 43
IN - India 42
CA - Canada 39
FI - Finlandia 38
AU - Australia 33
PL - Polonia 24
MX - Messico 22
ID - Indonesia 19
TR - Turchia 19
AR - Argentina 18
JP - Giappone 16
NL - Olanda 16
UA - Ucraina 16
IQ - Iraq 13
CO - Colombia 11
ZA - Sudafrica 9
AT - Austria 8
BE - Belgio 7
SA - Arabia Saudita 7
UZ - Uzbekistan 7
DZ - Algeria 6
NG - Nigeria 6
PH - Filippine 6
TN - Tunisia 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CG - Congo 5
CL - Cile 5
ES - Italia 5
MA - Marocco 5
PK - Pakistan 5
TG - Togo 5
JO - Giordania 4
LT - Lituania 4
MY - Malesia 4
PE - Perù 4
AL - Albania 3
AZ - Azerbaigian 3
CH - Svizzera 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
EC - Ecuador 3
EU - Europa 3
KE - Kenya 3
LV - Lettonia 3
RO - Romania 3
BY - Bielorussia 2
ET - Etiopia 2
GR - Grecia 2
JM - Giamaica 2
NO - Norvegia 2
NP - Nepal 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
IL - Israele 1
IR - Iran 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MM - Myanmar 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
Totale 6.649
Salva come PNG Salva come JPEG
Città #
Singapore 354
Ashburn 315
Chandler 293
Moscow 288
San Jose 259
Dallas 234
Southend 229
Hong Kong 180
Beijing 146
Dublin 93
The Dalles 86
Woodbridge 83
Council Bluffs 81
Verona 75
New York 51
Los Angeles 50
Ho Chi Minh City 49
Ann Arbor 48
Wilmington 41
Lawrence 40
Princeton 40
Jinan 34
Shenyang 34
Hanoi 31
Jacksonville 30
São Paulo 28
Perth 26
Sindelfingen 26
Buffalo 25
Nanjing 25
Columbus 23
Munich 22
Redondo Beach 19
Montreal 18
Warsaw 18
Santa Clara 17
Tokyo 16
Tianjin 15
Chennai 14
Helsinki 14
Nuremberg 14
Orem 14
Phoenix 14
Falls Church 13
San Francisco 13
Zhengzhou 13
Hebei 12
London 12
Taiyuan 12
Milan 11
Poplar 11
Bologna 10
Changsha 10
Houston 10
Mexico City 10
Redmond 10
Rome 10
Seoul 10
Toronto 10
Atlanta 9
Dong Ket 9
Guangzhou 9
Jakarta 9
Nanchang 9
Redwood City 9
Belo Horizonte 8
Rio de Janeiro 8
Seattle 8
Stockholm 8
Brussels 7
Denver 7
Frankfurt am Main 7
Norwalk 7
Porto Alegre 7
Taizhou 7
Tashkent 7
Thái Nguyên 7
Ankara 6
Chengdu 6
Chicago 6
Haikou 6
Haiphong 6
Kent 6
Kyiv 6
New Delhi 6
Ningbo 6
Querétaro 6
Abuja 5
Amsterdam 5
Basingstoke 5
Brasília 5
City of London 5
Da Nang 5
Düsseldorf 5
Falkenstein 5
Johannesburg 5
Lomé 5
Shanghai 5
Washington 5
Bergamo 4
Totale 3.955
Salva come PNG Salva come JPEG
Nome #
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 250
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 246
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 217
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 202
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 200
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 196
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 186
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 185
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 181
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 177
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 176
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 176
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 174
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 173
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 166
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 164
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 162
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 157
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 155
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 153
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 152
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 152
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 152
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 150
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 146
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 144
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 139
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 137
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC” 126
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 119
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 113
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 111
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 111
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective {RUX}-{IOL} study 105
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 105
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 104
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 104
Management of Chronic Myeloid Leukemia in Advanced Phase 103
Second cancers in MPN: Survival analysis from an international study 79
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 77
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 77
Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity 72
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 69
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 68
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 66
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 66
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 65
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 56
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 50
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 31
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study 1
Totale 6.746
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.298
article - articoli 19.563
book - libri 0
conference - conferenze 4.735
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.596
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 0 0 0 0 0 0 23
2021/2022308 31 80 16 40 10 10 6 14 11 2 14 74
2022/2023711 42 82 69 121 72 167 3 41 77 11 14 12
2023/2024398 11 36 19 52 33 32 14 18 10 41 102 30
2024/20251.078 46 57 39 187 60 39 83 76 137 67 97 190
2025/20263.330 217 188 206 542 838 192 287 179 306 209 38 128
Totale 6.746